MedTrace Logo

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

NCT07257185 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-03-30

No results posted yet for this study

Summary

The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.

Conditions

  • Thyroid Eye Disease (TED)

Interventions

DRUG

MHB018A injection

MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

DRUG

MHB018A injection Placebo

6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

Sponsors & Collaborators

  • Minghui Pharmaceutical (Hangzhou) Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-17
Primary Completion
2027-08-31
Completion
2028-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07257185 on ClinicalTrials.gov